Clinical Decisions
Powered by Immunix

We remove the guesswork. Now you can prioritize therapy for the sickest patients with our new dimension of biological patient data – saving lives and money.

Learn More

Precision Medicine
Needs Better Data

We created a proprietary, high quality database of new promising biomarker data and clinical data to understand the atypical immune response.


Unravelling Biological Complexity

Our advanced machine learning algorithms decode a patient's individual immune profile and predict future outcomes based on our database of historical patient data and outcomes.

We help physicians

Prioritize patients. Deliver the Right Therapy, Faster.

In hospitals today, physicians use isolated, non-specific clinical parameters, such as temperature, heart rate, and blood pressure, but are missing critical biological data that more accurately indicates the patient's health status.

At Prenosis, our decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes for existing patients and accelerate optimal therapy.

We provide physicians with real-time information to improve outcomes and reduce hospital costs.

Our Vision Graphic

Confidence in Outcomes

Our growing, proprietary ImmunoMap enables rapid precision medicine based on evidence from multiple clinical sites1.


Biomarker measurements


Clinical data parameters


Comprehensive maps of human immune response

Introducing Immunix

Physicians make clinical decisions with incomplete information on the patient's full immune profile, which can delay therapy or result in sub-optimal antibiotic selection2.

Our portfolio of decision support tools allows physicians to understand an individual patient's risk profile and prescribe the optimal therapy faster than ever before.

Immunix Table

How It Works

How It Works - Step 1


Medical history and bloodwork are collected and tested for patients suspected of having an abnormal immune response.

How It Works - Step 2


Patient's full immune profile is compared to the Prenosis historical dataset using advanced machine learning algorithms in the cloud to rapidly identify the patients at risk of severe outcomes.

How It Works - Step 3


Immunix uses that information to inform the physician's selected treatment pathway and accelerate optimal therapy.

Potential Benefits for U.S. Hospitals

Based on a 1,600 patient, multi-site study3

Reduce mortality


lives per year
Decrease hospital costs


per year
Reduce Hospital
Length of Stay


hospital days per year

Passionate. Experienced. Practical.

At Prenosis, we are driven to decode the atypical human immune response with simple, easy-to-use tools that help physicians improve patient care and outcomes. Our team has both the expertise and experience to deliver on that promise.

Management Team

Bobby Reddy, Jr., Ph.D.

Bobby Reddy, Jr., Ph.D.


Bobby has led the company from inception, driving company vision, building the team, securing clinical and strategic partnerships, and raising funds...

Angela McFarland, CPA, MBA

Angela McFarland, CPA, MBA

Chief Financial Officer

Angela is a seasoned CFO with over 15 years experience leading organizations in the biotechnology industry and start-up environment. Previously, she held...

Carlos Lopez-Espina, MS

Carlos Lopez-Espina, MS

Director of Analytics

Carlos is an innovator and multidisciplinary problem solver focused on biotechnology, clinical research and product development. Over the last 15 years...

>David Sihai Zhao, Ph.D.

David Sihai Zhao, Ph.D.

Head of Algorithm Development

Dave has specialized in statistical techniques for analyzing large-scale data from high-throughput biological datasets for over 11 years, and has...

Rashid Bashir, Ph.D.

Rashid Bashir, Ph.D.

Board Member and Co-Founder

Rashid is an innovation leader in the development of new technologies in the biotechnology field. He has a proven track record of successfully transitioning...


Sean Murphy

Sean is the Executive Vice President of Malin Life Sciences Holding, a publicly traded investment company. Sean was a co-founder of Malin, which has invested approximately $500 Million dollars of...

Mark Wagner

Mark has more than 30 years of global experience in the medical device industry. He most recently served as the President and CEO of Celleration until its acquisition by Alliqua ...

Edward Ogunro, Ph.D.

Ed served as the Chief Scientific Officer and Senior VP of Research & Development and Regulatory Affairs at Hospira for 4 years. Prior to that, he was the Corporate VP of Hospital Products Research...

John Landgraf

John most recently served as the Executive VP of Nutritional Products, one of Abbott's largest businesses. Prior to this, he held roles as the Senior VP of Global Pharmaceutical Manufacturing and Supply...

Edwin Moore

Ed is a currently a visiting scientist at the Beckman Institute and an EIR mentor at EnterpriseWorks at UIUC, in addition to serving as the president and co-founder of BioPhia...

Get in touch.

Chicago Office

3440 S Dearborn Street, Suite 222S

Chicago, IL 60616


Subscribe to our newsletter!

* indicates required
Fill out my online form.